Peptide Schedule
Cerluten6 residuesAEDPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Cerluten
Benefits
About Cerluten
Cerluten is a natural polypeptide bioregulator complex classified as Cytomax A-5 in Khavinson's peptide bioregulator system. It's produced by extracting low-molecular-weight peptides (up to 10,000 Da) from the cerebral cortex of young calves using a patented isolation and fractionation process developed at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike single-sequence synthetic peptides such as Cortagen or Pinealon, Cerluten contains a mixture of brain-derived peptides that are proposed to act on neural tissue through tissue-specific gene regulation. The primary clinical evidence comes from an open-label study conducted in 2003-2004 at the St. Petersburg Institute, involving 48 patients with CNS conditions including traumatic brain injury sequelae, post-stroke states, and vascular encephalopathy. The study reported positive clinical outcomes in 64.6% of treated patients, with improvements in memory, cognitive function, headache intensity, emotional balance, and sleep quality. However, the study lacked blinding, randomization, and independent replication. It's important to recognize that Cerluten's evidence base has significant limitations. All published clinical data comes from a single institution — the same one that developed the product. There are no controlled human trials in international peer-reviewed journals, no formal pharmacokinetic studies, and no independent safety evaluations. The peptide complex is classified as a dietary supplement in Russia, not a registered pharmaceutical. Researchers interested in brain-derived peptide bioregulators should note that the synthetic derivative Cortagen and the related polypeptide extract Cortexin have somewhat more published data in the international literature.
Who Should Consider Cerluten
- Researchers studying brain-derived peptide bioregulators and tissue-specific gene regulation
- Individuals exploring Khavinson bioregulator protocols for cognitive and CNS support
- Those interested in non-injection peptide options for neuroprotective research
- Aging research subjects investigating epigenetic approaches to cognitive decline
- Clinicians familiar with Russian peptide bioregulator protocols seeking adjunctive CNS support options
How Cerluten Works
Cerluten's proposed mechanism centers on tissue-specific gene regulation by brain-derived short peptides. The low-molecular-weight peptides in the complex are small enough to penetrate both cell membranes and the nuclear envelope, where they're thought to interact directly with DNA and chromatin structures. Research on component peptides (Glu-Asp-Arg and Lys-Glu-Asp) has shown they can stimulate serotonin expression in aging brain cortex cell cultures by regulating the 5-tryptophan hydroxylase gene through complementary binding to a specific CCTGCC nucleotide sequence. This represents a proposed epigenetic mechanism — the peptides influence gene transcription without altering the underlying DNA sequence. At the chromatin level, brain-derived short peptides have been demonstrated to induce selective deheterochromatinization, potentially reactivating genes that become silenced during aging. The complex is also proposed to reduce neuronal apoptosis through modulation of oxidative stress pathways and to balance neuroinflammatory responses. These mechanisms remain largely theoretical for Cerluten as a whole, since most published molecular studies have been conducted on isolated synthetic peptides (like Cortagen) rather than the full polypeptide mixture.
What to Expect
No well-documented acute effects. Based on the broader bioregulator model, gene expression changes may begin within the first week. Some users anecdotally report subtle improvements in sleep quality.
Continued proposed gene modulation. In the open-label clinical study, early improvements in headache intensity and emotional balance were noted during the treatment course.
Full course completion. Clinical observations suggest peak improvements in memory, cognitive function, and overall neurological status toward the end of the 30-day course.
Effects from epigenetic remodeling and gene expression changes are proposed to persist beyond the active dosing period. The bioregulator model suggests sustained activity for several months, which is why courses are repeated only 2-3 times per year.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | 2x Daily |
| Aggressive | 40mg | 2x Daily |
Note: Cerluten (Cytomax A-5) is a natural polypeptide bioregulator complex extracted from the cerebral cortex of young calves, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It contains low-molecular-weight peptides up to 10,000 Da, including amino acids such as glutamic acid, aspartic acid, alanine, leucine, valine, isoleucine, proline, and serine. Each capsule contains 10 mg of active peptide complex. As an oral capsule, it doesn't require reconstitution. Standard protocols involve 10-30 day courses taken 2-3 times per year. The related synthetic tetrapeptide Cortagen (Ala-Glu-Asp-Pro) was derived from amino acid analysis of this same cerebral cortex source material.
How to Inject Cerluten
Cerluten is taken as an oral capsule, making it one of the most straightforward peptide bioregulators to use. Take 1-2 capsules once or twice daily, preferably 15-30 minutes before meals with a glass of water. Standard research protocols use 10-20 mg per day for maintenance and up to 40 mg per day for acute conditions. A typical course lasts 30 days and is repeated every 3-6 months. For acute CNS conditions, some protocols use 1-2 capsules 2-3 times daily for 10-20 days. No reconstitution or injection is required. Store capsules at room temperature away from direct sunlight and moisture.
Cycling Protocol
Standard Khavinson bioregulator protocol: 10-30 day courses taken 2-3 times per year with at least 3-month intervals between courses. For acute conditions, shorter 10-20 day courses with 2-3 capsules daily may be used. Some practitioners suggest pairing with Pinealon for combined CNS support.
Pharmacokinetics
Source: Estimated from general low-molecular-weight peptide kinetics; no formal PK studies published for Cerluten polypeptide complex
Loading the interactive decay curve.
Side Effects
Cerluten hasn't been evaluated in controlled safety trials, so the side effect profile is poorly characterized. In the single published clinical study of 48 patients, no adverse effects, toxic reactions, or allergic responses were reported. As a polypeptide complex derived from bovine cerebral cortex, theoretical concerns include individual hypersensitivity reactions, mild gastrointestinal discomfort, and — although unconfirmed — the general risks associated with animal-derived tissue extracts (batch-to-batch variability, potential immunogenicity). No formal toxicology studies, drug interaction assessments, or reproductive toxicity data have been published. The safety profile is largely inferred from the broader class of Khavinson bioregulators, which have been used in Russia for decades without widely reported adverse events, though this doesn't substitute for controlled safety data.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to bovine-derived products or any component of the formulation
- Children under 18 (insufficient pediatric data)
- Active malignancy (theoretical concern with gene expression modulation)
- Individuals with prion disease risk factors (bovine-derived tissue extract)
- Severe allergic conditions or history of anaphylaxis to animal-derived products
Drug Interactions
- No formal drug interaction studies have been published
- Theoretical additive effects when combined with other neuroprotective peptides (Cortexin, Cerebrolysin, Cortagen, Semax)
- Use caution with serotonergic medications (SSRIs, SNRIs, MAOIs) given the proposed serotonin-modulating activity of component peptides
- May theoretically interact with CNS-active medications due to gene expression effects in neural tissue
- No known interactions with common supplements or vitamins
Storage & Stability
Molecular Profile
Related Peptides
References
- Neuroprotective effects of peptides bioregulators in people of various agePubMed 24738258
- Short peptides stimulate serotonin expression in cells of brain cortexPubMed 24909721
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies resultsPubMed 24003726
- Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's DiseasePubMed 35457077
- Neuroprotective Effects of Peptides in the Brain: Transcriptome ApproachPubMed 32564732
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarrayPubMed 15159690
- Peptide bioregulation of aging: results and prospectsPubMed 19830585
- Neuroprotective effects of peptidesPubMed 32593244